Compugen Ltd. operates as a specialized therapeutic discovery enterprise that leverages its proprietary computational biology infrastructure to uncover novel drug targets for immunotherapy. Rather than relying solely on traditional laboratory experimentation, its computational platform analyzes vast genomic and proteomic datasets to predict immune system pathways, allowing the company to advance innovative cancer treatments both independently and through strategic pharmaceutical licensing collaborations.